GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jinhe Biotechnology Co Ltd (SZSE:002688) » Definitions » Piotroski F-Score

Jinhe Biotechnology Co (SZSE:002688) Piotroski F-Score : 5 (As of May. 26, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Jinhe Biotechnology Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jinhe Biotechnology Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Jinhe Biotechnology Co's Piotroski F-Score or its related term are showing as below:

SZSE:002688' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Jinhe Biotechnology Co was 8. The lowest was 2. And the median was 5.


Jinhe Biotechnology Co Piotroski F-Score Historical Data

The historical data trend for Jinhe Biotechnology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jinhe Biotechnology Co Piotroski F-Score Chart

Jinhe Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 5.00 6.00 3.00 5.00

Jinhe Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 5.00 5.00 5.00

Competitive Comparison of Jinhe Biotechnology Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Jinhe Biotechnology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jinhe Biotechnology Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jinhe Biotechnology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Jinhe Biotechnology Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 52.439 + 13.706 + -16.608 + 45.143 = ¥95 Mil.
Cash Flow from Operations was 110.802 + 80.841 + 28.474 + 73.39 = ¥294 Mil.
Revenue was 505.189 + 537.37 + 604.286 + 519.45 = ¥2,166 Mil.
Gross Profit was 153.49 + 179.61 + 154.329 + 177.567 = ¥665 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(4573.099 + 5058.393 + 5347.01 + 5453.807 + 5589.5) / 5 = ¥5204.3618 Mil.
Total Assets at the begining of this year (Mar23) was ¥4,573 Mil.
Long-Term Debt & Capital Lease Obligation was ¥804 Mil.
Total Current Assets was ¥2,133 Mil.
Total Current Liabilities was ¥2,099 Mil.
Net Income was 54.92 + 15.766 + -26.841 + 36.92 = ¥81 Mil.

Revenue was 605.646 + 507.442 + 489.852 + 527.286 = ¥2,130 Mil.
Gross Profit was 164.128 + 145.015 + 146.666 + 155.068 = ¥611 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(4204.623 + 4299.65 + 4647.052 + 4508.51 + 4573.099) / 5 = ¥4446.5868 Mil.
Total Assets at the begining of last year (Mar22) was ¥4,205 Mil.
Long-Term Debt & Capital Lease Obligation was ¥374 Mil.
Total Current Assets was ¥1,809 Mil.
Total Current Liabilities was ¥1,628 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jinhe Biotechnology Co's current Net Income (TTM) was 95. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jinhe Biotechnology Co's current Cash Flow from Operations (TTM) was 294. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=94.68/4573.099
=0.02070368

ROA (Last Year)=Net Income/Total Assets (Mar22)
=80.765/4204.623
=0.01920862

Jinhe Biotechnology Co's return on assets of this year was 0.02070368. Jinhe Biotechnology Co's return on assets of last year was 0.01920862. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Jinhe Biotechnology Co's current Net Income (TTM) was 95. Jinhe Biotechnology Co's current Cash Flow from Operations (TTM) was 294. ==> 294 > 95 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=803.799/5204.3618
=0.15444718

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=374.204/4446.5868
=0.08415533

Jinhe Biotechnology Co's gearing of this year was 0.15444718. Jinhe Biotechnology Co's gearing of last year was 0.08415533. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=2132.526/2099.03
=1.01595785

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=1808.957/1628.053
=1.11111678

Jinhe Biotechnology Co's current ratio of this year was 1.01595785. Jinhe Biotechnology Co's current ratio of last year was 1.11111678. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Jinhe Biotechnology Co's number of shares in issue this year was 781.023. Jinhe Biotechnology Co's number of shares in issue last year was 780.551. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=664.996/2166.295
=0.30697389

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=610.877/2130.226
=0.28676629

Jinhe Biotechnology Co's gross margin of this year was 0.30697389. Jinhe Biotechnology Co's gross margin of last year was 0.28676629. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=2166.295/4573.099
=0.47370394

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=2130.226/4204.623
=0.506639

Jinhe Biotechnology Co's asset turnover of this year was 0.47370394. Jinhe Biotechnology Co's asset turnover of last year was 0.506639. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+0+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jinhe Biotechnology Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Jinhe Biotechnology Co  (SZSE:002688) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Jinhe Biotechnology Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Jinhe Biotechnology Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Jinhe Biotechnology Co (SZSE:002688) Business Description

Traded in Other Exchanges
N/A
Address
Zone B3 Xinghai Plaza, 1-7-2 Building 27, Shahekou District, Dalian, CHN, 116023
Jinhe Biotechnology Co Ltd is engaged in manufacturing veterinary feed additives, veterinary vaccines, veterinary chemicals, corn starch processing and industrial wastewater treatment business.
Executives
Wang Zhi Jun Directors, executives
Liu Ying Chun Executives
Deng Yi Xin Secretary Dong
Li Fu Zhong Director
Liu Yun Tian Directors, executives
Xie Chang Xian Directors, executives
Wang Dong Xiao Director
Yao Jian Xiong Supervisors
Zheng Liu Ji Supervisors
Niu You Shan Executives
Wu Ming Xia Director
Li Wei Qi Directors, executives
Wu Rui Gang Executives

Jinhe Biotechnology Co (SZSE:002688) Headlines

No Headlines